Trial Profile
An expanded-access, open-label study of the safety and tolerability of PEGASYS alone and in combination with ribavirin in patients with chronic hepatitis C.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2010
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Roche